CA2779497A1 - The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders - Google Patents

The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders Download PDF

Info

Publication number
CA2779497A1
CA2779497A1 CA2779497A CA2779497A CA2779497A1 CA 2779497 A1 CA2779497 A1 CA 2779497A1 CA 2779497 A CA2779497 A CA 2779497A CA 2779497 A CA2779497 A CA 2779497A CA 2779497 A1 CA2779497 A1 CA 2779497A1
Authority
CA
Canada
Prior art keywords
dinaline
subject
day
administered
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2779497A
Other languages
English (en)
French (fr)
Inventor
Li-Huei Tsai
Ji-Song Guan
Stephen J. Haggarty
Edward Holson
Florence Wagner
Johannes Graeff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
Broad Institute Inc
Original Assignee
General Hospital Corp
Massachusetts Institute of Technology
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Institute of Technology, Broad Institute Inc filed Critical General Hospital Corp
Publication of CA2779497A1 publication Critical patent/CA2779497A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2779497A 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders Abandoned CA2779497A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25692709P 2009-10-30 2009-10-30
US61/256,927 2009-10-30
US26546809P 2009-12-01 2009-12-01
US61/265,468 2009-12-01
PCT/US2010/054872 WO2011053876A1 (en) 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Publications (1)

Publication Number Publication Date
CA2779497A1 true CA2779497A1 (en) 2011-05-05

Family

ID=43922604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779497A Abandoned CA2779497A1 (en) 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Country Status (9)

Country Link
US (2) US8563615B2 (cg-RX-API-DMAC7.html)
EP (1) EP2493298A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013509441A (cg-RX-API-DMAC7.html)
CN (1) CN102834002A (cg-RX-API-DMAC7.html)
AU (1) AU2010313255B2 (cg-RX-API-DMAC7.html)
CA (1) CA2779497A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03807A (cg-RX-API-DMAC7.html)
NZ (1) NZ599757A (cg-RX-API-DMAC7.html)
WO (1) WO2011053876A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
IN2012DN03807A (cg-RX-API-DMAC7.html) 2009-10-30 2015-08-28 Massachusetts Inst Technology
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
EP3483150A1 (en) 2011-07-22 2019-05-15 Massachusetts Institute Of Technology Activators of class 1 histone deacetylases (hdacs) and uses thereof
US9790184B2 (en) 2012-07-27 2017-10-17 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20150219673A1 (en) * 2012-09-04 2015-08-06 Massachusetts Institute Of Technology The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
GB202001023D0 (en) * 2020-01-24 2020-03-11 Univ Leicester HDAC Degrader
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
WO2023034440A1 (en) * 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
ATE361316T1 (de) 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US20060148743A1 (en) 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
US7199227B2 (en) 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
WO2003048774A1 (en) 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
EP1472216A2 (en) 2002-02-07 2004-11-03 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US20050118596A1 (en) 2002-02-08 2005-06-02 Asselbergs Fredericus Alphonsus M. Method for screening for compounds having hdac inhibitory activity
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040077591A1 (en) 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
US7282608B2 (en) 2002-10-17 2007-10-16 Methylgene, Inc. Inhibitors of histone deacetylase
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
JP5319113B2 (ja) 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2005102358A2 (en) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Silicone-substituted cox-2 selective inhibitors
ES2308065T3 (es) 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
US20060008517A1 (en) 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
EP1817020A4 (en) 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20070015183A1 (en) 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
CA2626898A1 (en) 2005-11-03 2007-05-18 Christopher Hamblett Substituted nicotinamide compounds
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
WO2007100657A2 (en) 2006-02-28 2007-09-07 Merck & Co., Inc. Inhibitors of histone deacetylase
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
JP2009535333A (ja) 2006-04-26 2009-10-01 メルク エンド カムパニー インコーポレーテッド 二置換アニリン化合物
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
WO2008008472A2 (en) 2006-07-13 2008-01-17 President And Fellows Of Harvard College Methods and compositions for modulating synapse formation
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US20110009475A1 (en) 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
US20100075926A1 (en) 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
CN102271763A (zh) 2008-12-03 2011-12-07 麻省理工学院 抑制hdac2以促进记忆
WO2010098888A1 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
IN2012DN03807A (cg-RX-API-DMAC7.html) 2009-10-30 2015-08-28 Massachusetts Inst Technology
EP3483150A1 (en) 2011-07-22 2019-05-15 Massachusetts Institute Of Technology Activators of class 1 histone deacetylases (hdacs) and uses thereof

Also Published As

Publication number Publication date
IN2012DN03807A (cg-RX-API-DMAC7.html) 2015-08-28
EP2493298A1 (en) 2012-09-05
US20120322879A1 (en) 2012-12-20
US8563615B2 (en) 2013-10-22
NZ599757A (en) 2014-08-29
WO2011053876A1 (en) 2011-05-05
US20110224303A1 (en) 2011-09-15
AU2010313255B2 (en) 2015-04-30
JP2013509441A (ja) 2013-03-14
US8841346B2 (en) 2014-09-23
EP2493298A4 (en) 2013-04-10
AU2010313255A1 (en) 2012-05-31
CN102834002A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
AU2010313255B2 (en) The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US11377423B2 (en) Inhibitors of histone deacetylase
JP6093180B2 (ja) ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
JP2012510512A (ja) 記憶を推進するためのｈｄａｃ２の阻害
WO2014100438A1 (en) Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JP2024097004A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
CN107095864A (zh) 组蛋白乙酰转移酶激活剂的用途
US20210038589A1 (en) Uses, compositions and methods
Diniz et al. Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by amyloid‐β (Aβ) oligomers
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
CN119546323A (zh) 用于治疗与bbb渗透性相关的障碍或疾病的爱帕琳肽受体调节剂
CN116981449A (zh) 用于引起神经保护的化合物和组合物
CN114521142A (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
US12384818B2 (en) Cyclin-dependent kinase 5 (CDK5) inhibitory peptides
JP2024517654A (ja) レチノイン酸受容体アルファと阻害剤との相互作用を安定化することによる、シャペロン媒介オートファジーを増加させる方法
WO2008141112A1 (en) Methods of treating rett syndrome

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161031